Trastuzumab drug data and news

---

Herceptin® Plus Doxil® Safe and Effective in Metastatic Breast ...  17 May 2006
According to an early online publication in the Journal of Clinical Oncology, the treatment combination consisting of Herceptin® (trastuzumab) plus Doxil ... - Cancer Consultants (press release),

ImmunoGen Agrees To Create Commercial Manufacturing Process For ...  May 4, 2006
...on Thursday said it entered into an collaboration agreement with Genentech to create a commercial manufacturing process for Genentech's trastuzumab-DM1 TAP ... - Trading Markets,

ImmunoGen to Develop Manufacturing Process for Trastuzumab-DM1 for ...  May 8, 2006
...that the Company has entered into an agreement to collaborate with Genentech to create a commercial manufacturing process for Genentech's trastuzumab-DM1 TAP ... - GenomicsProteomics.com (press release),

DRUGS IN DEVELOPMENT  May 4, 2006
...to Develop Commercial-Scale Manufacturing Process for Trastuzumab-DM1 for Genentech; Companies Also Amend 2000 Agreement for TAP Compounds Targeting HER2 ... - PharmaLive.com (press release),

Genentech Announces Vice President Appointments in Commercial ...  May 11, 2006
In this role, Miller will be responsible for leading all sales and marketing activities for Herceptin(R) (Trastuzumab) and Tarceva(R) (erlotinib). ... - Finanzen.net,

Gene amplification could guide treatment for high-risk breast ...  May 11, 2006
...all patients with tumors with HER2/neu amplification would receive adjuvant therapy with a chemotherapy agent and the targeted therapy trastuzumab (Herceptin). ... - News-Medical.net,

æ?¥æº?：生命ç»?纬  Apr 28, 2006
This study is the first to indicate that the drug Trastuzumab, also known as Herceptin, may work better when it is followed by injections of interleukin 12 or ... - BioX,

Kosan Announces Clinical Data to be Presented at the 2006 Annual ...  May 8, 2006
...clinical trials of its lead heat shock protein 90 (Hsp90) inhibitor product candidate, KOS-953, administered in combination with trastuzumab (Herceptin®) in ... - Yahoo! News (press release)

Herceptin Receives Positive Opinion in Europe for Early Use in ...  Apr 28, 2006
European Union's Committee for Human Medicinal Products (CHMP) has issued a positive recommendation for the use of Herceptin (trastuzumab) following surgery ... - DG News

ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2006 Financial ...  May 4, 2006
It targets the CD33 antigen found on acute myeloid leukemia cells. Trastuzumab-DM1 - This compound is in development by Genentech. ... - Genetic Engineering News,

Intrathecal Herceptin® May Halt Cancer Progression Within the ...  Apr 24, 2006
According to a recent article published in Oncology Reports, administration of Herceptin® (trastuzumab) into the central nervous system (CNS) may help to slow ... - Cancer Consultants (press release),

Herceptin Receives Positive Opinion in Europe for Early Use in ...  Apr 27, 2006
References: [i] Harries M, Smith I. The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 9: 75-85, 2002. ... - news aktuell (Pressemitteilung),

Researchers detail new studies and findings in the area of breast ...  Apr 20, 2006
States and Italy. Study 1: Breast cancer volume falls after tumors receive lapatinib plus trastuzumab. "Lapatinib (GW572016) is ... - Therapeutics Daily (subscription) (press release),

COMUNICADO: Herceptin Receives Positive Opinion in Europe for ...  Apr 27, 2006
...[iv] Romond, E., Perez, E. et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2 Positive Breast Cancer. New England Journal of Medicine 353:16 2005. ... - Europa Press,

ImmunoGen Shares Rise on Genentech Deal  May 4, 2006
In addition, the companies agreed to collaborate to create a commercial manufacturing process for Genentech's drug trastuzumab-DMI, and Immunogen will receive ... - Houston Chronicle,

Study provides data for price-setting policies related to ...  Apr 20, 2006
According to a study from Belgium, "Herceptin (trastuzumab) is a humanized monoclonal antibody that is being tested in the adjuvant setting. ... - Therapeutics Daily (subscription) (press release),

Breast cancer fine needle aspiration cytology specimens contain ...  May 4, 2006
...and HER2 gene amplification in breast cancer are prognostic factors for the response to specific medical treatments such as trastuzumab, endocrine therapy, and ... - Therapeutics Daily (subscription) (press release),

Herceptin® May Change the Natural History of Patients with HER2 ...  May 1, 2006
Italian researchers have reported that patients with HER2-positive breast cancer treated with Herceptin (trastuzumab) and Navelbine® (vinorelbine) have better ... - Cancer Consultants (press release),

Additional Evidence that Herceptin® Benefits Women with HER2 ...  Apr 17, 2006
...to the results of a study conducted in Italy, women with metastatic HER2-positive breast cancer who were treated with Herceptin® (trastuzumab) and Navelbine ... - Cancer Consultants (press release),

New hope on breast cancer drug  Apr 18, 2006
...the Breast Cancer Network. HERCEPTIN (trastuzumab) is used in the treatment of metastatic breast cancer. Metastatic breast cancer ... - The Age,

Australia's medicines regulator close to decision on herceptin  Apr 20, 2006
...to conditionally approve an application by Roche Products Pty Limited to extend the registration of the breast cancer drug Herceptin (trastuzumab) for use in ... - News-Medical.net,

ImmunoGen, Inc. Announces Conference Call to Discuss its Third ...  Apr 27, 2006
...aventis Group. A fourth TAP compound, trastuzumab-DM1 in development by Genentech, now has an effective IND. Genentech, Centocor ... - Genetic Engineering News,

Collaboration Can Advance Pharmacogenomics  Apr 17, 2006
On a small scale, pharmaceutical products such as Herceptin (trastuzumab, used to treat breast cancer) and Gleevec (imatinib, used to treat tumors) have been ... - Genomics & Proteomics (subscription),

Herceptin wins record EU nod for early breast cancer  Apr 28, 2006
Roche's phenomenally successful breast cancer drug Herceptin (trastuzumab) has been pushed through the European approvals system in record time and now looks ... - Pharma Times (subscription),

Taxotere®, Platinol®, and Herceptin® for Locally Advanced HER2 ...  Apr 24, 2006
...the University of California at Los Angeles have reported that a regimen of Taxotere (docetaxel), Platinol (cisplatin) and Herceptin (trastuzumab) results in ... - Cancer Consultants (press release),